Visual functioning and health-related quality of life in diabetic patients about to undergo anti-vascular endothelial growth factor treatment for sight-threatening macular edema

Journal of Diabetes and Its Complications
Therese GranströmElisabet Granstam

Abstract

To examine patient-reported outcome (PRO) in a selected group of Swedish patients about to receive anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular edema (DME). In this cross-sectional study, 59 patients with diabetes mellitus, who regularly visited the outpatient eye-clinics, were included. Sociodemographic and clinical data were collected and the patients completed PRO measures before starting anti-VEGF treatment. PRO measures assessed eye-specific outcomes (NEI-VFQ-25) and generic health-related quality of life (SF-36). The participants consisted of 30 men and 29 women (mean age, 68.5years); 54 (92%) patients had type 2 diabetes; 5 (9%) patients had moderate or severe visual impairment; 28 (47%) were classified as having mild visual impairment. Some of the patients reported overall problems in their daily lives, such as with social relationships, as well as problems with impaired sight as a result of reduced distance vision. Further studies are needed to investigate PRO factors related to low perceived general health in this patient population. It is important to increase our understanding of such underlying mechanisms to promote improvements in the quality of patient care.

References

Aug 10, 1999·Diabetes/metabolism Research and Reviews·R R Rubin, M Peyrot
Sep 18, 2003·Ophthalmology·C P WilkinsonUNKNOWN Global Diabetic Retinopathy Project Group
Jan 30, 2008·American Journal of Ophthalmology·Flavio E HiraiRonald Klein
Mar 11, 2009·Archives of Ophthalmology·UNKNOWN Diabetic Retinopathy Clinical Research Network (DRCR.net)Craig Kollman
Apr 30, 2010·Ophthalmology·UNKNOWN Diabetic Retinopathy Clinical Research NetworkJennifer K Sun
Feb 15, 2012·Ophthalmology·Quan Dong NguyenUNKNOWN RISE and RIDE Research Group
Apr 28, 2012·Ophthalmology·Diana V DoUNKNOWN da Vinci Study Group
May 16, 2012·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Emelie HeintzLars-Åke Levin
Jan 26, 2013·Journal of Health Psychology·Jennifer A Janzen ClaudeLindsay Friesen
Apr 10, 2013·Scandinavian Journal of Caring Sciences·Karin WikbladJaneth K Leksell
Dec 18, 2013·Investigative Ophthalmology & Visual Science·Gerard A Lutty
Mar 26, 2014·The British Journal of Ophthalmology·Rupert R A BourneUNKNOWN Vision Loss Expert Group of the Global Burden of Disease Study
Jul 12, 2014·Ophthalmology·Jean-François KorobelnikDavid M Brown
Jan 1, 2013·Health Services Insights·Theresa Weldring, Sheree M S Smith
Aug 16, 2014·JAMA Ophthalmology·Rohit VarmaAdam Turpcu
Aug 26, 2014·Ophthalmology·Neil M BresslerUNKNOWN RIDE and RISE Research Groups
Mar 31, 2015·Journal of Diabetes and Its Complications·Elif Betul TurkogluGursoy Alagoz

❮ Previous
Next ❯

Citations

Mar 18, 2019·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Krystal KhooEva K Fenwick
Nov 16, 2018·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Johnny N Mahlangu
Jun 3, 2020·Cornea·Megan M TuohyMaria A Woodward

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.